IR-MED Follow-up (additional info, -Thanks Vintool
Post# of 85475
(Total Views: 383)
Posted On: 02/13/2024 2:22:05 PM
IR-MED Follow-up (additional info, -Thanks Vintool)
02/13/2024
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-MED Inc. announces final data from a study conducted at Clalit medical centers on PressureSafe, an AI-driven technology for pressure injury detection. The study results will be presented at the NPIAP 2024 Annual Conference, showcasing PressureSafe's efficacy in early-stage pressure injury detection.
Final results to be reported from a study conducted at two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest in Israel.
PressureSafe, for the detection of pressure injuries, addresses a healthcare challenge that costs $26.8 billion and causes 60,000 deaths annually in the U.S. alone
Rosh Pina, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from a study conducted at two medical centers, Beit Rivka Hospital, and Rabin Medical Center, both in Petah Tikva and owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest in Israel, will be presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference which will take place in San Antonio, Texas on February 16-17, 2024.
The study’s Principal Investigator, Dr. Gal Maydan, of Beit Rivka Hospital Geriatric Rehabilitation Center, will present the data in a poster titled “Near Infra-Red Spectroscopy for early detection of stage 1 pressure injury and deep tissue injury – clinical study results”.
The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe™, IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection. IR-MED’s clinical and execute team will demonstrate PressureSafe at booth #102 at NPIAP 2024, which is attended by the world’s top thought leaders and practitioners in the prevention and treatment of pressure injuries.
“We are eager to share the results coming out of this collaborative study with Clalit, where real-world data was gathered at two hospitals, with hundreds of PressureSafe scans conducted on patients by hospital nurses and staff. We are grateful to the entire team at Clalit and to Dr. Gal Maydan for leading the study,” stated Tzur Di-Cori, IR-MED’s CEO. “PressureSafe’s non-invasive, skin color agnostic approach to detecting early-stage pressure injuries has the potential to significantly diminish the incidence pressure injuries and corresponding human suffering and medical costs.”
PressureSafe, an innovative non-invasive medical device that uses infrared optical spectroscopy and an AI-based algorithm, is designed to effectively detect early-stage pressure injuries for all skin tones. Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
PressureSafe was found to be over 90% accurate in detecting pressure injuries based on interim results from a multicenter study. Since Infra Read is agnostic to skin color the device shall effectively address equity in healthcare by using infrared light to detect biomarker changes below the skin’s surface.
About IR-MED
IR-MED Inc. is developing a noninvasive spectrographic analysis technology platform, allowing healthcare professionals to detect, measure, and monitor, in real-time, different molecules in the blood, in human tissue, and in body fluids without invasive procedures. PressureSafe, the first product under development, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone as it calibrates personally to each patient’s skin.
IR-MED’s technology is being developed to allow accurate readings of biomarkers in a non-invasive method, that may provide caregiver the optimal decision support system in cases where uncertainties disturb physicians in their decision processes.
IR-MED holds patents protecting its technology and innovations in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.
PressureSafe is currently undergoing usability studies at multiple medical centers. It is not yet available for commercial use.
02/13/2024
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-MED Inc. announces final data from a study conducted at Clalit medical centers on PressureSafe, an AI-driven technology for pressure injury detection. The study results will be presented at the NPIAP 2024 Annual Conference, showcasing PressureSafe's efficacy in early-stage pressure injury detection.
Final results to be reported from a study conducted at two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest in Israel.
PressureSafe, for the detection of pressure injuries, addresses a healthcare challenge that costs $26.8 billion and causes 60,000 deaths annually in the U.S. alone
Rosh Pina, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from a study conducted at two medical centers, Beit Rivka Hospital, and Rabin Medical Center, both in Petah Tikva and owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest in Israel, will be presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference which will take place in San Antonio, Texas on February 16-17, 2024.
The study’s Principal Investigator, Dr. Gal Maydan, of Beit Rivka Hospital Geriatric Rehabilitation Center, will present the data in a poster titled “Near Infra-Red Spectroscopy for early detection of stage 1 pressure injury and deep tissue injury – clinical study results”.
The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe™, IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection. IR-MED’s clinical and execute team will demonstrate PressureSafe at booth #102 at NPIAP 2024, which is attended by the world’s top thought leaders and practitioners in the prevention and treatment of pressure injuries.
“We are eager to share the results coming out of this collaborative study with Clalit, where real-world data was gathered at two hospitals, with hundreds of PressureSafe scans conducted on patients by hospital nurses and staff. We are grateful to the entire team at Clalit and to Dr. Gal Maydan for leading the study,” stated Tzur Di-Cori, IR-MED’s CEO. “PressureSafe’s non-invasive, skin color agnostic approach to detecting early-stage pressure injuries has the potential to significantly diminish the incidence pressure injuries and corresponding human suffering and medical costs.”
PressureSafe, an innovative non-invasive medical device that uses infrared optical spectroscopy and an AI-based algorithm, is designed to effectively detect early-stage pressure injuries for all skin tones. Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
PressureSafe was found to be over 90% accurate in detecting pressure injuries based on interim results from a multicenter study. Since Infra Read is agnostic to skin color the device shall effectively address equity in healthcare by using infrared light to detect biomarker changes below the skin’s surface.
About IR-MED
IR-MED Inc. is developing a noninvasive spectrographic analysis technology platform, allowing healthcare professionals to detect, measure, and monitor, in real-time, different molecules in the blood, in human tissue, and in body fluids without invasive procedures. PressureSafe, the first product under development, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone as it calibrates personally to each patient’s skin.
IR-MED’s technology is being developed to allow accurate readings of biomarkers in a non-invasive method, that may provide caregiver the optimal decision support system in cases where uncertainties disturb physicians in their decision processes.
IR-MED holds patents protecting its technology and innovations in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.
PressureSafe is currently undergoing usability studies at multiple medical centers. It is not yet available for commercial use.
(13)
(0)Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼